Quest Diagnostics Incorporated
corporate_fare Company Profile
Quest Diagnostics Incorporated (NYSE:DGX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for DGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for DGX spans 10-Q, 8-K, FWP, 10-K.
Recent high-impact activity:
- Quest Diagnostics 10-Q Details Q3 EPS of $2.78, $797M Cash and New Lab-Asset Deal
- Q3 Beat and Raised Guidance Overshadowed by Cyber Incident at Quest
- Quest Diagnostics Lifts Full-Year 2026 Revenue and EPS Outlook
- Quest Diagnostics Discloses Breach of Quanum LSM System; Patient Records Accessed
- Quest Diagnostics Tops Q3 Estimates and Lifts Full-Year Revenue and EPS Guidance
Financial Snapshot
Short Interest & Short Volume
3.64 days to coverFINRA reported short interest of 3,734,103 shares in DGX as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 59.0% of DGX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.